Results 71 to 80 of about 6,396 (177)

Solubility data of deferiprone in propylene glycol and 1-propanol mixtures at 293.2–323.2 K

Chemical Thermodynamics and Thermal Analysis
Experimental determination on solubility of deferiprone in propylene glycol + 1-propanol mixtures and their saturated solution's densities were reported at atmospheric pressure (101 kPa) from 293.2 to 313.2 K.
Homa Rezaei, Elaheh Rahimpour, Abolghasem Jouyban   +2 more
doaj   +1 more source

Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing remitting multiple sclerosis subjects [PDF]

, 2011
T cells are important mediators of autoimmune inflammation in relapsing remitting multiple sclerosis (RRMS). Previous studies found that deferiprone, an iron chelator, suppressed disease activity in a mouse model of multiple sclerosis, and inhibition of ...
Garcia, Sharon L., Sweeney, Matthew E., Lynch, Sharon G., Rues, Laura, Sharon L. Garcia, Matthew E. Sweeney, Slusser, Joyce G., Sharon G. Lynch, Stephen H. Benedict, Benedict, Stephen H., Laura Rues, Joyce G. Slusser, LeVine, Steven M., Steven M. LeVine   +13 more
core   +1 more source

The optimization of iron chelation with deferiprone

, 1997
grantor: University of TorontoDeferiprone is an orally active iron-chelating agent that reduces the body iron burden of chronically transfused, iron-overloaded homozygous beta-thalassemia patients.
Fassos, Frank Fotios
core  

An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload

, 2019
Introduction: Congenital hemoglobinopathies represent the most severe forms of anemia in Europe requiring treatment that include regular blood transfusions and iron chelators administered alone or in combination.
Mariagrazia Felisi (4001651), Viviana Giannuzzi (4001669), Rosa Conte (4001675), Fedele Bonifazi (4001648), Adriana Ceci (4001666), Donato Bonifazi (4001660), Antonella Didio (6739616)   +6 more
core   +1 more source

Challenges of Iron Chelation in Thalassemic Children

Thalassemia Reports
Thalassemia treatment still relies on supportive care, mainly including blood transfusion and iron chelation therapy. Iron chelation is considered the main factor responsible for the marked improvement in survival rates of thalassemic patients ...
Alkistis Adramerina, Marina Economou
doaj   +1 more source

Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration

Frontiers in Molecular Neuroscience, 2018
There is an emerging link between the accumulation of iron in the brain and abnormal tau pathology in a number of neurodegenerative disorders, such as Alzheimer’s disease (AD).
Shalini S. Rao, Paul Anthony Adlard
doaj   +1 more source

Molecular formula of deferiprone and speciation plots of its variously protonated forms.

, 2015
Molecular formula of deferiprone and speciation plots of its variously protonated forms.
Miriam Crespo-Alonso (772616), Raffaela Biesuz (772620), Giancarla Alberti (772619), Valeria Marina Nurchi (772615), Gavino Sanna (772617), Guido Crisponi (772614), Maria Antonietta Zoroddu (772618)   +6 more
core   +1 more source

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients [PDF]

, 2010
BACKGROUND: Iron overload is a predictable and life-threatening complication in patients dependent on the regular transfusion of RBCs. The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic
유철주, 원성철
core   +1 more source

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction

Journal of Cardiovascular Magnetic Resonance, 2008
Background In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur.
Pibiri Martina, Agus Annalisa, Westwood Mark A, Smith Gillian C, Dessi Carlo, Galanello Renzo, Tanner Mark A, Nair Sunil V, Walker J Malcolm, Pennell Dudley J   +9 more
doaj   +1 more source

Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis

Haematologica, 2003
BACKGROUND AND OBJECTIVES: Iron-induced cardiac disease remains the main cause of death in patients with thalassemia major, despite chelation therapy with deferoxamine.
A Piga, C Gaglioti, E Fogliacco, F Tricta   +3 more
doaj